A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

Morris D. Groves, Moshe H. Maor, Christina Meyers, Athanassios P. Kyritsis, Kurt A. Jaeckle, W. K Alfred Yung, Raymond E. Sawaya, Kenneth Hess, Janet M. Bruner, Pamela Peterson, Victor A. Levin

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose: To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme. Methods and Materials: Between 1994 and 1996, 88 patients were enrolled to receive 1,9 Gy of radiation three times a day for two 5-day cycles separated by 2 weeks; each 5-day cycle was preceded by a continuous 96-hour infusion of BrdU at a dose of 2.1 g/m2/day. After radiotherapy, patients received PCV chemotherapy. Results: Median survival for all 88 patients was 50 weeks, seventy (79.5%) received one or more courses of PCV; their median survival was 57 weeks. Covariates predictive of improved survival were gross total versus subtotal resection or biopsy (p = 0.0048) and radiation dose ≥ 56 Gy (p = 0.019). While receiving BrdU, 47 patients (53%) suffered grade 3 or 4 thrombocytopenia or leukopenia; 22 patients (25%) suffered grade 3 or 4 dermatologic toxicity. Conclusion: Survival was not extended in patients with glioblastoma or gliosarcoma who received BrdU at the dose and administration schedule used in this study. The BrdU dose used in this study resulted in substantial myelosuppressive and dermatologic toxicity.

Original languageEnglish (US)
Pages (from-to)127-135
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume45
Issue number1
DOIs
StatePublished - Aug 1 1999
Externally publishedYes

Fingerprint

Lomustine
Procarbazine
Vincristine
Bromodeoxyuridine
Glioblastoma
fractionation
radiation therapy
Radiotherapy
dosage
Survival
chemotherapy
toxicity
grade
leukopenia
Gliosarcoma
Radiation Dosage
Drug Therapy
cycles
Leukopenia
radiation

Keywords

  • Accelerated fractionated radiotherapy
  • Bromodeoxyuridine (BrdU)
  • Glioblastoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. / Groves, Morris D.; Maor, Moshe H.; Meyers, Christina; Kyritsis, Athanassios P.; Jaeckle, Kurt A.; Yung, W. K Alfred; Sawaya, Raymond E.; Hess, Kenneth; Bruner, Janet M.; Peterson, Pamela; Levin, Victor A.

In: International Journal of Radiation Oncology Biology Physics, Vol. 45, No. 1, 01.08.1999, p. 127-135.

Research output: Contribution to journalArticle

Groves, Morris D. ; Maor, Moshe H. ; Meyers, Christina ; Kyritsis, Athanassios P. ; Jaeckle, Kurt A. ; Yung, W. K Alfred ; Sawaya, Raymond E. ; Hess, Kenneth ; Bruner, Janet M. ; Peterson, Pamela ; Levin, Victor A. / A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. In: International Journal of Radiation Oncology Biology Physics. 1999 ; Vol. 45, No. 1. pp. 127-135.
@article{a82e973ab3994f208b235253aaad6055,
title = "A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme",
abstract = "Purpose: To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme. Methods and Materials: Between 1994 and 1996, 88 patients were enrolled to receive 1,9 Gy of radiation three times a day for two 5-day cycles separated by 2 weeks; each 5-day cycle was preceded by a continuous 96-hour infusion of BrdU at a dose of 2.1 g/m2/day. After radiotherapy, patients received PCV chemotherapy. Results: Median survival for all 88 patients was 50 weeks, seventy (79.5{\%}) received one or more courses of PCV; their median survival was 57 weeks. Covariates predictive of improved survival were gross total versus subtotal resection or biopsy (p = 0.0048) and radiation dose ≥ 56 Gy (p = 0.019). While receiving BrdU, 47 patients (53{\%}) suffered grade 3 or 4 thrombocytopenia or leukopenia; 22 patients (25{\%}) suffered grade 3 or 4 dermatologic toxicity. Conclusion: Survival was not extended in patients with glioblastoma or gliosarcoma who received BrdU at the dose and administration schedule used in this study. The BrdU dose used in this study resulted in substantial myelosuppressive and dermatologic toxicity.",
keywords = "Accelerated fractionated radiotherapy, Bromodeoxyuridine (BrdU), Glioblastoma",
author = "Groves, {Morris D.} and Maor, {Moshe H.} and Christina Meyers and Kyritsis, {Athanassios P.} and Jaeckle, {Kurt A.} and Yung, {W. K Alfred} and Sawaya, {Raymond E.} and Kenneth Hess and Bruner, {Janet M.} and Pamela Peterson and Levin, {Victor A.}",
year = "1999",
month = "8",
day = "1",
doi = "10.1016/S0360-3016(99)00122-4",
language = "English (US)",
volume = "45",
pages = "127--135",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

AU - Groves, Morris D.

AU - Maor, Moshe H.

AU - Meyers, Christina

AU - Kyritsis, Athanassios P.

AU - Jaeckle, Kurt A.

AU - Yung, W. K Alfred

AU - Sawaya, Raymond E.

AU - Hess, Kenneth

AU - Bruner, Janet M.

AU - Peterson, Pamela

AU - Levin, Victor A.

PY - 1999/8/1

Y1 - 1999/8/1

N2 - Purpose: To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme. Methods and Materials: Between 1994 and 1996, 88 patients were enrolled to receive 1,9 Gy of radiation three times a day for two 5-day cycles separated by 2 weeks; each 5-day cycle was preceded by a continuous 96-hour infusion of BrdU at a dose of 2.1 g/m2/day. After radiotherapy, patients received PCV chemotherapy. Results: Median survival for all 88 patients was 50 weeks, seventy (79.5%) received one or more courses of PCV; their median survival was 57 weeks. Covariates predictive of improved survival were gross total versus subtotal resection or biopsy (p = 0.0048) and radiation dose ≥ 56 Gy (p = 0.019). While receiving BrdU, 47 patients (53%) suffered grade 3 or 4 thrombocytopenia or leukopenia; 22 patients (25%) suffered grade 3 or 4 dermatologic toxicity. Conclusion: Survival was not extended in patients with glioblastoma or gliosarcoma who received BrdU at the dose and administration schedule used in this study. The BrdU dose used in this study resulted in substantial myelosuppressive and dermatologic toxicity.

AB - Purpose: To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme. Methods and Materials: Between 1994 and 1996, 88 patients were enrolled to receive 1,9 Gy of radiation three times a day for two 5-day cycles separated by 2 weeks; each 5-day cycle was preceded by a continuous 96-hour infusion of BrdU at a dose of 2.1 g/m2/day. After radiotherapy, patients received PCV chemotherapy. Results: Median survival for all 88 patients was 50 weeks, seventy (79.5%) received one or more courses of PCV; their median survival was 57 weeks. Covariates predictive of improved survival were gross total versus subtotal resection or biopsy (p = 0.0048) and radiation dose ≥ 56 Gy (p = 0.019). While receiving BrdU, 47 patients (53%) suffered grade 3 or 4 thrombocytopenia or leukopenia; 22 patients (25%) suffered grade 3 or 4 dermatologic toxicity. Conclusion: Survival was not extended in patients with glioblastoma or gliosarcoma who received BrdU at the dose and administration schedule used in this study. The BrdU dose used in this study resulted in substantial myelosuppressive and dermatologic toxicity.

KW - Accelerated fractionated radiotherapy

KW - Bromodeoxyuridine (BrdU)

KW - Glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=0032801217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032801217&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(99)00122-4

DO - 10.1016/S0360-3016(99)00122-4

M3 - Article

VL - 45

SP - 127

EP - 135

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -